odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
4588
10.69690/ODMJ-019-0829-4588
Opinion
Harnessing Real-World Evidence to Support Precision Oncology
Westphalen
C. Benedikt
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;
Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Munich, Munich, Germany;
Christoph_Benedikt.Westphalen@med.uni-muenchen.de
02
09
2025
ODMJ-019-0829-4588
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
precision oncology
Real-World Evidence
production-ready-file-url
[
Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024 Jul;35(7):588-606.
]
[
Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022 Apr 10;40(11):1231-58.
]
[
Moscow JA, Fojo T, Schilsky RL, et al. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 Mar;15(3):183-92.
]
[
Luo J, Solit DB, et al. Leveraging real-world data to advance biomarker discovery and precision oncology. Cancer Cell. 2025 Apr 14;43(4):606-10.
]
[
Christopoulos P, Schlenk R, Kazdal D, et al. Real-world data for precision cancer medicine: a European perspective. Genes Chromosomes Cancer. 2023 Sep;62(9):557-63.
]
[
Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, et al. Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022 Apr 1;28(7):1402-11.
]
[
van der Velden DL, Hoes LR, van der Wijngaart H, et al. The Drug Rediscovery Protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 Oct;574(7776):127-31.
]
[
Pugh TJ, Bell JL, Bruce JP, et al. AACR Project GENIE: 100,000 cases and beyond. Cancer Discov. 2022 Sep 2;12(9):2044-57.
]
[
AACR Project GENIE Consortium, et al. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017 Aug;7(8):818-31.
]
[
Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Ann Oncol. 2018 Sep 1;29(9):1895-902.
]
[
Westphalen CB, Boscolo Bielo L, Aftimos P, et al. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Ann Oncol. 2025 Jun;36(6):614-25.
]
[
Casolino R, Beer PA, Chakravarty D, et al. Interpreting and integrating genomic test results in clinical cancer care: overview and practical guidance. CA Cancer J Clin. 2024 May-Jun;74(3):264-85.
]
[
Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022 Apr;28(4):658-65.
]